JAC Advance Access originally published online on January 9, 2007
Journal of Antimicrobial Chemotherapy 2007 59(3):517-524; doi:10.1093/jac/dkl501
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection
1 Department of Virology, Royal Free Hospital and Royal Free & University College Medical School, London, UK 2 Department of Thoracic and HIV Medicine, Royal Free Hospital, London, UK 3 Department of Primary Care and Population Sciences, Royal Free & University College Medical School, London, UK
Received 18 August 2006; returned 18 October 2006; revised 6 November 2006; accepted 15 November 2006
* Corresponding author. Tel: +44-20-77940500; Fax: +44-20-78302854; E-mail: a.geretti{at}medsch.ucl.ac.uk
Objectives: To determine prevalence and predictors of antiretroviral drug resistance in newly diagnosed individuals with HIV-1 infection, using a systematic approach to avoid selection bias.
Methods: Plasma samples from all persons diagnosed HIV-1 seropositive at a large London centre between April 2004 and February 2006 underwent sequencing of HIV-1 reverse transcriptase (RT) and protease genes. Subtype was assigned by phylogenetic analysis. Resistance was scored according to the IAS-USA list (2005) modified to include T215revertants and exclude isolated E44D or V118I and minor protease mutations. Recent seroconversion was identified by HIV antibody avidity testing.
Results: The cohort of 239 included 169 (70.7%) males, 126 (52.7%) homosexuals, 118 (49.5%) persons of white ethnicity and 144 (60.0%) persons born outside the UK. Subtypes included B 134 (56.1%), C 46 (19.2%), A 17 (7.1%), other non-B 42 (17.6%). The prevalence of resistance mutations was 17/239 (7.1%; 95% confidence interval 4.5–11.1%), comprising 10/239 (4.2%) nucleoside/nucleotide RT inhibitor (NRTI); 4/239 (1.7%) non-nucleoside RT inhibitor (NNRTI) and 4/239 (1.7%) protease inhibitor (PI) associated mutations. Dual-class (NRTI + PI) resistance mutations were detected in 1/239 (0.4%) person. The prevalence of resistance mutations was 7/85 (8.2%) and 10/154 (6.5%) in persons with recent and established infection, respectively. In multivariate analysis, having been born in the UK and high CD4 count, but not gender, age, risk group, ethnicity or subtype, were independent predictors of resistance.
Conclusions: In an unselected UK cohort, subtypes other than B accounted for 43.9% of new HIV-1 diagnoses. The prevalence of resistance mutations was 7.1% and highest in those born in the UK.
Keywords: mutations , avidity , subtype , HIV , drug naive
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. A. I. Payne, E. F. Nsutebu, E. R. Hunter, O. Olarinde, P. Collini, J. A. T. Dunbar, M. S. T. Basta, J. W. T. Elston, M. L. Schmid, H. Thaker, et al. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort J. Antimicrob. Chemother., September 1, 2008; 62(3): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sagir, M. Oette, R. Kaiser, M. Daumer, G. Fatkenheuer, J. K. Rockstroh, H. Knechten, G. Schmutz, M. Hower, J. Emmelkamp, et al. Trends of prevalence of primary HIV drug resistance in Germany J. Antimicrob. Chemother., October 1, 2007; 60(4): 843 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Booth and A. M. Geretti Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection J. Antimicrob. Chemother., June 1, 2007; 59(6): 1047 - 1056. [Abstract] [Full Text] [PDF]
|
|